Navigation Links
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults

CONCERTA(R) now available for patients with ADHD ages 6 to 65

RARITAN, N.J., June 27 /PRNewswire/ -- ADHD is the most common emotional, cognitive and behavioral disorder treated in children(1), and according to the National Institute of Mental Health (NIMH), between 30 percent and 70 percent of children with ADHD continue to exhibit symptoms in the adult years(2). ADHD is thought to affect about eight million, or one in 20, adults in the United States(3), and research on the life span of the condition notes the disorder impairs academic, social and occupational functioning(1), and is associated with academic underachievement, conduct problems, underemployment, motor vehicle safety and difficulties with personal relationships(1).

Today, there's a new treatment option for the millions of adults in the United States with ADHD: Johnson & Johnson Pharmaceutical Research & Development L.L.C. (J&JPRD) announced the U.S. Food and Drug Administration (FDA) approved J&JPRD's Supplemental New Drug Application (sNDA) for CONCERTA(R) treatment of ADHD in adults ages 18 to 65. The doses approved for adults range from 18 to 72 mg daily.

Today's approval expands the CONCERTA(R) indication from children and adolescents into adults with ADHD, and offers these patients a patented once- daily formulation. Using its unique OROS(R) delivery system, the CONCERTA(R) formulation delivers an initial dose of medication when the tablet is ingested. Medication is then delivered into the bloodstream at a controlled rate throughout the day.

The CONCERTA(R) brand, which was the first 12-hour extended-release methylphenidate (MPH) treatment for ADHD, is the market leader for MPH treatment of children and adolescents with ADHD. CONCERTA(R) is marketed in the United States by McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

"What we've seen in the growing body of knowledge on adult ADHD suggests a challenging burden of impairment in everyday functioning," said Janet Vergis, President of McNeil Pediatrics(TM). "Recognizing this need -- and as the market leader in extended-release MPH for children and adolescents -- we see today's approval as a treatment option milestone for adults with ADHD and their healthcare professionals. We are proud to offer patients ages 6 to 65 with ADHD our CONCERTA(R) product knowledge based on more than seven years of clinical experience."

Researchers examining ADHD across the lifespan have noted the condition is often chronic, with prominent symptoms and impairment spanning into adulthood, and is often associated with co-occurring anxiety, mood and disruptive disorders as well as substance abuse(3). According to the NIMH, ADHD is thought to be a biological condition, usually inherited, and tends to run in some families more than others. Often when a child is diagnosed with the disorder, a parent will recognize that he or she had many of the same symptoms, and for the first time, will begin to understand some of the traits that have troubled them for years(4). All aspects of an individual's life must be considered in the diagnosis and treatment of ADHD(3).

Today's FDA approval was based on clinical trial data in adults ages 18 to 65. In these studies, use of CONCERTA(R) was shown to significantly improve ADHD symptoms such as attention, impulsivity and hyperactivity compared to placebo, and the medication was shown to be generally well tolerated.


CONCERTA(R) is approved for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.


Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.

CONCERTA(R) should not be taken by patients who have: allergies to methylphenidate or other ingredients in CONCERTA(R); significant anxiety, tension, or agitation; glaucoma; tics, Tourette's syndrome, or family history of Tourette's syndrome; current or past use of monoamine oxidase inhibitor (MAOI); esophagus, stomach, or intestinal narrowing. Children under six years of age should not take CONCERTA(R).

Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs; has had any heart problems, heart defects, high blood pressure, or a family history of these problems; has had depression, abnormal thoughts or visions, bipolar disorder, or seizure. Contact your healthcare professional immediately if you or your child: develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity; or if aggressive behavior or hostility develops or worsens while taking CONCERTA(R).

Stimulants may impair the ability of the patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA(R) does not adversely affect your ability to engage in such activities.

The most common adverse reaction (> 5%) reported in children and adolescents was upper abdominal pain. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia.

Visit for complete prescribing information.

About McNeil Pediatrics

McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is committed to meeting the needs of pediatric medicine through the development of therapies specifically formulated for children. McNeil Pediatrics markets CONCERTA(R) for the treatment of children, adolescents and adults with ADHD in the United States. McNeil Pediatrics continues to explore other new therapies to meet the needs of children and the pediatric community. Visit for more information.

About J&JPRD

Johnson & Johnson Pharmaceutical Research & Development L.L.C. (J&JPRD) is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Asia, Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.


(1) Wilens, T.E., Dodson, W. A Clinical Perspective of Attention-Deficit Hyperactivity Disorder into Adulthood. Journal of Clinical Psychology 65:10. October 2004.

(2) National Institute of Mental Health. "ADHD in Adults." Available at disorder-adhd/index.shtml. Accessed June 19, 2008.

(3) Wilens, T.E., Biederman J., Spencer T.J. Attention Deficit/Hyperactivity Disorder Across the Lifespan. Annual Review of Medicine, Vol. 53. 2002.

(4) National Institute of Mental Health. "Genetics." Available at hyperactivity-disorder-in-adults.shtml. Accessed June 19, 2008.

Media Investors

Tricia Geoghegan: (609) 730-3746 Louise Mehrotra: (732) 524-6491 Johnson & Johnson

Lesley Fishman: (732) 524-3922

Johnson & Johnson

SOURCE Johnson & Johnson Pharmaceutical Research & DevelopmentL.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
3. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
6. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
7. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
8. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
9. Medicare Approves in Home Sleep Apnea Testing
10. 3SBio Inc. Approves Share Repurchase Program
11. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ... Laurin , President and Chief Executive Officer of ProMetic, will ... 27 th Annual Healthcare Conference to be held at ... st , at 8.50am (ET) and ProMetic,s management ... The presentation will be available live via a webcast accessible ...
(Date:11/24/2015)... , November 24, 2015 , ... a European healthcare fund ... companies will work closely together in identifying European breakthrough technologies ... need. The collaboration is underpinned by a significant investment by ... is the first investment by Bristol-Myers Squibb in a European ...
(Date:11/23/2015)... 23, 2015   Ceres, Inc . (Nasdaq: ... results for the fiscal year ended August 31, 2015 ... --> --> During fiscal year ... feed products with a better balance of yield, energy ... agreements with several leading crop input providers and made ...
Breaking Biology Technology:
(Date:11/19/2015)... Nov. 19, 2015  Based on its in-depth analysis ... recognizes BIO-key with the 2015 Global Frost & Sullivan ... & Sullivan presents this award to the company that ... the needs of the market it serves. The award ... and expands on customer base demands, the overall impact ...
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
Breaking Biology News(10 mins):